-+ 0.00%
-+ 0.00%
-+ 0.00%
US FDA: GLP-1 receptor agonists are required to change safety labels because they may increase the risk of rare but serious eye diseases.
Share
Listen to the news
US FDA: GLP-1 receptor agonists are required to change safety labels because they may increase the risk of rare but serious eye diseases.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending